Miraculins to showcase study results at ACG m
Miraculins to showcase study results at ACG meeting
2006-09-20 09:17 ET - News Release
Dr. Jim Charlton reports
MIRACULINS TO PRESENT STUDY RESULTS AT MAJOR GASTROENTEROLOGY CONFERENCE
Miraculins Inc. will be presenting results from the recent verification study for its colorectal cancer diagnostic at the annual American College of Gastroenterology scientific meeting being held in Las Vegas from Oct. 20, 2006, to Oct. 25, 2006.
The results of the verification study, announced in Stockwatch in May, 2006, introduced a panel of markers that provided a sensitivity and specificity of greater than 80 per cent and 80 per cent, respectively. The test is being developed as a cancer screen that can independently distinguish between healthy patients, those with benign polyps and those with cancerous lesions.
"The ACG annual meeting is the major event for presenting the latest advances in GI technology and patient-related clinical data," said Dr. Jim Charlton, president of Miraculins. "We are pleased to be discussing our results with colleagues at the world's most prestigious conference on gastroenterology."
Miraculins purchased the intellectual property for its colorectal cancer diagnostic as part of a 2005 technology acquisition from Europroteome AG, a German-based proteomics research company. The verification study was based on Miraculins's research using samples from the same patients that Europroteome used for the original discovery study. A validation study in collaboration with Fox Chase Cancer Center is currently under way.
About the American College Gastroenterology
The American College of Gastroenterology is a recognized leader in educating GI professionals and the general public about digestive disorders. Its mission is to serve the evolving needs of physicians in the delivery of high-quality scientific, humanistic and cost-effective health care to gastroenterology patients. The ACG conference is considered the premier GI clinical event of the year.
About colorectal cancer
Colorectal cancer is one of the most prevalent cancers in North America, with over 150,000 new cases diagnosed each year. The American Cancer Society recommends annual screening for colorectal cancer for all persons over 50 years of age. Current diagnostic methods for colorectal cancer are predominantly image-based, invasive and expensive, resulting in low compliance in the general population. The diagnosis of colorectal cancer could be dramatically improved with the availability of reliable biomarker-based tests.
We seek Safe Harbor.
Top